DexCom (DXCM) PT Raised to $270 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $82.97 --0%
Rating Summary:
33 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 7
Rating Summary:
33 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 11 | New: 7
Join SI Premium – FREE
Morgan Stanley analyst David Lewis raised the price target on DexCom (NASDAQ: DXCM) to $270.00 (from $225.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- Enel SpA (ENEL:IM) (ENLAY) PT Lowered to EUR10.35 at UBS
- DexCom (DXCM) PT Raised to $93 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
